Pierfrancesco Tassone
Pierfrancesco Tassone
Professor of Medical Oncology, Magna Graecia University, Catanzaro, Italy
Geverifieerd e-mailadres voor unicz.it
Titel
Geciteerd door
Geciteerd door
Jaar
Mir-34: a new weapon against cancer?
G Misso, MT Di Martino, G De Rosa, AA Farooqi, A Lombardi, V Campani, ...
Molecular therapy-nucleic acids 3, e195, 2014
4072014
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
M Fulciniti, P Tassone, T Hideshima, S Vallet, P Nanjappa, SA Ettenberg, ...
Blood, The Journal of the American Society of Hematology 114 (2), 371-379, 2009
3872009
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
P Tassone, P Tagliaferri, A Perricelli, S Blotta, B Quaresima, ML Martelli, ...
British journal of cancer 88 (8), 1285-1291, 2003
3772003
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
L Catley, E Weisberg, T Kiziltepe, YT Tai, T Hideshima, P Neri, P Tassone, ...
Blood 108 (10), 3441-3449, 2006
3542006
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 …
A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ...
The Lancet Oncology 17 (3), 367-377, 2016
3492016
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
E Carbone, P Neri, M Mesuraca, MT Fulciniti, T Otsuki, D Pende, V Groh, ...
Blood 105 (1), 251-258, 2005
3202005
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The Lancet Oncology 18 (12), 1688-1700, 2017
2902017
Dysfunctional T regulatory cells in multiple myeloma
RH Prabhala, P Neri, JE Bae, P Tassone, MA Shammas, CK Allam, ...
Blood 107 (1), 301-304, 2006
2382006
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy
P Correale, MS Rotundo, MT Del Vecchio, C Remondo, C Migali, ...
Journal of immunotherapy 33 (4), 435-441, 2010
2052010
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence
MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ...
Clinical cancer research 18 (22), 6260-6270, 2012
2042012
Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines
P Tassone, S Forciniti, E Galea, G Morrone, MC Turco, V Martinelli, ...
Leukemia 14 (5), 841-844, 2000
1892000
Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro
P Tassone, P Tagliaferri, C Viscomi, C Palmieri, M Caraglia, ...
British journal of cancer 88 (12), 1971-1978, 2003
1812003
Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells
MF Romano, A Lamberti, P Tassone, F Alfinito, S Costantini, F Chiurazzi, ...
Blood, The Journal of the American Society of Hematology 92 (3), 990-995, 1998
1751998
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
D Chauhan, P Neri, M Velankar, K Podar, T Hideshima, M Fulciniti, ...
Blood 109 (3), 1220-1227, 2007
1662007
miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease
M Rossi, MR Pitari, N Amodio, MT Di Martino, F Conforti, E Leone, C Botta, ...
Journal of cellular physiology 228 (7), 1506-1515, 2013
1612013
Cytotoxic activity of the maytansinoid immunoconjugate B-B4–DM1 against CD138+ multiple myeloma cells
P Tassone, VS Goldmacher, P Neri, A Gozzini, MA Shammas, ...
Blood 104 (12), 3688-3696, 2004
1602004
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells
P Tassone, A Gozzini, V Goldmacher, MA Shammas, KR Whiteman, ...
Cancer research 64 (13), 4629-4636, 2004
1582004
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth
E Leone, E Morelli, MT Di Martino, N Amodio, U Foresta, A Gullą, M Rossi, ...
Clinical Cancer Research 19 (8), 2096-2106, 2013
1552013
A clinically relevant SCID-hu in vivo model of human multiple myeloma
P Tassone, P Neri, DR Carrasco, R Burger, VS Goldmacher, R Fram, ...
Blood 106 (2), 713-716, 2005
1512005
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
N Amodio, MT Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, ...
Cell death & disease 3 (11), e436-e436, 2012
1502012
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20